Senators want probe of biologic companies’ practices
Senate Judiciary Committee Chairman Charles Grassley and Senator Amy Klobuchar have asked the Federal Trade Commission to investigate whether makers of biologic medicines are using practices that hinder or delay biosimilars...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: